MX370361B - Preparación farmacéutica que contiene compuesto de ácido piridilaminoacético. - Google Patents
Preparación farmacéutica que contiene compuesto de ácido piridilaminoacético.Info
- Publication number
- MX370361B MX370361B MX2016009063A MX2016009063A MX370361B MX 370361 B MX370361 B MX 370361B MX 2016009063 A MX2016009063 A MX 2016009063A MX 2016009063 A MX2016009063 A MX 2016009063A MX 370361 B MX370361 B MX 370361B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical preparation
- acetic acid
- intraocular pressure
- lowering
- acid compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Un objetivo de la presente invención es encontrar cual de un número enorme de compuestos de ácido piridilaminoacético tiene un efecto de disminución de presión intraocular particularmente excelente y se puede utilizar como un agente terapéutico o preventivo para glaucoma o hipertensión ocular o un agente de disminución de presión intraocular, y encontrar cómo el compuesto encontrado se utiliza y/o que dosis del compuesto se instila a un paciente (principalmente, un humano) para lograr un efecto terapéutico o preventivo efectivo. Se proporciona una preparación farmacéutica para tratamiento o prevención de glaucoma o hipertensión ocular, que comprende 0.0003 a 0.01% (p/v) de (6-{[4-(pirazol-1-il)bencil] (piridin-3-ilsulfonil)aminometil}piri din-2-ilamino) acetato de isopropilo o una sal del mismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461925882P | 2014-01-10 | 2014-01-10 | |
PCT/JP2015/050366 WO2015105144A1 (ja) | 2014-01-10 | 2015-01-08 | ピリジルアミノ酢酸化合物を含む医薬製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016009063A MX2016009063A (es) | 2016-09-28 |
MX370361B true MX370361B (es) | 2019-12-10 |
Family
ID=53520400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016009063A MX370361B (es) | 2014-01-10 | 2015-01-08 | Preparación farmacéutica que contiene compuesto de ácido piridilaminoacético. |
Country Status (26)
Country | Link |
---|---|
US (8) | US9415038B2 (es) |
EP (3) | EP3093018B1 (es) |
JP (6) | JP5846338B2 (es) |
KR (1) | KR101824829B1 (es) |
CN (2) | CN105899209B (es) |
AU (1) | AU2015205188B2 (es) |
BR (1) | BR112016015763B8 (es) |
CA (1) | CA2936026C (es) |
CL (1) | CL2016001756A1 (es) |
DK (1) | DK3093018T3 (es) |
EA (1) | EA031734B1 (es) |
ES (2) | ES2834334T3 (es) |
GE (1) | GEP20186917B (es) |
HK (1) | HK1223036A1 (es) |
HU (1) | HUE041653T2 (es) |
IL (1) | IL246447B (es) |
MX (1) | MX370361B (es) |
MY (1) | MY163235A (es) |
PH (1) | PH12016501357B1 (es) |
PL (1) | PL3093018T3 (es) |
PT (1) | PT3093018T (es) |
SG (1) | SG11201605653RA (es) |
TR (1) | TR201902019T4 (es) |
TW (1) | TWI598113B (es) |
UA (1) | UA117506C2 (es) |
WO (1) | WO2015105144A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2015205268B2 (en) * | 2014-01-10 | 2019-03-14 | Santen Pharmaceutical Co., Ltd. | Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition |
EP3093019B1 (en) | 2014-01-10 | 2021-05-26 | Santen Pharmaceutical Co., Ltd | Pharmaceutical composition containing pyridylamino acetic acid compound |
CA2936026C (en) | 2014-01-10 | 2022-04-19 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical preparation containing pyridylaminoacetic acid compound |
KR20170093839A (ko) * | 2014-12-12 | 2017-08-16 | 코와 가부시키가이샤 | 수성 조성물 |
TWI755356B (zh) * | 2015-07-01 | 2022-02-21 | 日商參天製藥股份有限公司 | 含檸檬酸酯之緩釋劑之用途 |
TWI794140B (zh) * | 2015-07-09 | 2023-03-01 | 日商參天製藥股份有限公司 | 含有吡啶基胺基乙酸化合物之預防及/或治療劑 |
WO2018230713A1 (ja) | 2017-06-16 | 2018-12-20 | 学校法人同志社 | カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用 |
CN110944668A (zh) | 2017-06-16 | 2020-03-31 | 学校法人同志社 | 用于治疗或预防眼部症状、障碍或疾病的包含mTOR抑制剂的药物及其应用 |
WO2019065838A1 (ja) | 2017-09-29 | 2019-04-04 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物を含有する医薬 |
JPWO2019124487A1 (ja) * | 2017-12-21 | 2020-12-10 | 参天製薬株式会社 | オミデネパグの組合せ |
WO2019131901A1 (ja) | 2017-12-28 | 2019-07-04 | 参天製薬株式会社 | ピリジルアミノ酢酸化合物を含有する医薬製剤 |
CA3162141A1 (en) * | 2018-04-24 | 2019-10-31 | Allergan, Inc. | Presbyopia treatments |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002356420A (ja) * | 2001-03-27 | 2002-12-13 | Santen Pharmaceut Co Ltd | 安定な水性液剤 |
PT2264009T (pt) * | 2008-03-12 | 2019-04-29 | Ube Industries | Composto do ácido piridilaminoacético |
EP2415763B1 (en) | 2009-03-30 | 2016-01-27 | Ube Industries, Ltd. | Pharmaceutical composition for treating or preventing glaucoma |
JP2011057633A (ja) * | 2009-09-11 | 2011-03-24 | Ube Industries Ltd | ピリジルアミノ酢酸化合物を含有する医薬 |
US20120202863A1 (en) * | 2011-02-03 | 2012-08-09 | Gerald Horn | Compositions and methods for treatment of glaucoma |
US9339496B2 (en) | 2012-07-13 | 2016-05-17 | Santen Pharmaceutical Co., Ltd. | Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist |
JP2014019650A (ja) * | 2012-07-13 | 2014-02-03 | Santen Pharmaceut Co Ltd | スルホンアミド化合物とタフルプロストの組み合わせ |
US20140018350A1 (en) | 2012-07-13 | 2014-01-16 | Asahi Glass Co., Ltd. | Combination of sulfonamide compound and tafluprost |
CA2878370C (en) * | 2012-07-13 | 2021-01-19 | Santen Pharmaceutical Co., Ltd. | Combinations comprising a sulfonamide compound for the treatment of glaucoma or ocular hypertension |
AU2015205268B2 (en) | 2014-01-10 | 2019-03-14 | Santen Pharmaceutical Co., Ltd. | Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition |
EP3093019B1 (en) | 2014-01-10 | 2021-05-26 | Santen Pharmaceutical Co., Ltd | Pharmaceutical composition containing pyridylamino acetic acid compound |
CA2936026C (en) | 2014-01-10 | 2022-04-19 | Santen Pharmaceutical Co., Ltd. | Pharmaceutical preparation containing pyridylaminoacetic acid compound |
-
2015
- 2015-01-08 CA CA2936026A patent/CA2936026C/en active Active
- 2015-01-08 ES ES18190494T patent/ES2834334T3/es active Active
- 2015-01-08 MY MYPI2016001271A patent/MY163235A/en unknown
- 2015-01-08 TW TW104100502A patent/TWI598113B/zh active
- 2015-01-08 CN CN201580003994.5A patent/CN105899209B/zh active Active
- 2015-01-08 PL PL15735133T patent/PL3093018T3/pl unknown
- 2015-01-08 EP EP15735133.9A patent/EP3093018B1/en active Active
- 2015-01-08 BR BR112016015763A patent/BR112016015763B8/pt active IP Right Grant
- 2015-01-08 MX MX2016009063A patent/MX370361B/es active IP Right Grant
- 2015-01-08 EP EP20183949.5A patent/EP3750541A1/en not_active Withdrawn
- 2015-01-08 UA UAA201607988A patent/UA117506C2/uk unknown
- 2015-01-08 AU AU2015205188A patent/AU2015205188B2/en active Active
- 2015-01-08 KR KR1020167018735A patent/KR101824829B1/ko active IP Right Grant
- 2015-01-08 TR TR2019/02019T patent/TR201902019T4/tr unknown
- 2015-01-08 DK DK15735133.9T patent/DK3093018T3/en active
- 2015-01-08 PT PT15735133T patent/PT3093018T/pt unknown
- 2015-01-08 EA EA201691402A patent/EA031734B1/ru unknown
- 2015-01-08 CN CN201811020654.5A patent/CN108743587B/zh active Active
- 2015-01-08 US US14/592,167 patent/US9415038B2/en active Active
- 2015-01-08 GE GEAP201514239A patent/GEP20186917B/en unknown
- 2015-01-08 ES ES15735133T patent/ES2711091T3/es active Active
- 2015-01-08 EP EP18190494.7A patent/EP3424503B1/en active Active
- 2015-01-08 WO PCT/JP2015/050366 patent/WO2015105144A1/ja active Application Filing
- 2015-01-08 JP JP2015527691A patent/JP5846338B2/ja active Active
- 2015-01-08 SG SG11201605653RA patent/SG11201605653RA/en unknown
- 2015-01-08 HU HUE15735133A patent/HUE041653T2/hu unknown
- 2015-11-09 JP JP2015219845A patent/JP6491588B2/ja active Active
-
2016
- 2016-06-26 IL IL246447A patent/IL246447B/en active IP Right Grant
- 2016-07-08 CL CL2016001756A patent/CL2016001756A1/es unknown
- 2016-07-08 PH PH12016501357A patent/PH12016501357B1/en unknown
- 2016-07-18 US US15/212,592 patent/US9943510B2/en not_active Ceased
- 2016-09-29 HK HK16111395.0A patent/HK1223036A1/zh unknown
-
2018
- 2018-02-13 US US15/895,100 patent/US10179127B2/en active Active
- 2018-08-28 US US16/114,721 patent/USRE48183E1/en active Active
- 2018-12-06 US US16/211,839 patent/US10702511B2/en active Active
-
2019
- 2019-03-01 JP JP2019037654A patent/JP6785330B2/ja active Active
-
2020
- 2020-05-29 US US16/887,108 patent/US11197849B2/en active Active
- 2020-10-26 JP JP2020178844A patent/JP7087040B2/ja active Active
-
2021
- 2021-11-08 US US17/521,031 patent/US11793798B2/en active Active
-
2022
- 2022-06-08 JP JP2022092999A patent/JP7402922B2/ja active Active
-
2023
- 2023-09-11 US US18/464,646 patent/US20240000763A1/en active Pending
- 2023-12-11 JP JP2023208468A patent/JP2024019479A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12016501357A1 (en) | Pharmaceutical preparation containing pyridylamino acetic acid compound | |
PH12018500212A1 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
NZ739211A (en) | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same | |
WO2016134223A3 (en) | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof | |
PH12016501394A1 (en) | Compounds for treating patients with ros1 mutant cancer cells | |
MX2019012884A (es) | Terapia de combinacion. | |
CA2883751A1 (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
WO2015020943A3 (en) | Digestive enzyme composition suitable for enteral administration | |
WO2017022962A8 (ko) | Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물 | |
RU2013150861A (ru) | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний | |
PH12015502406A1 (en) | Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof | |
MX2021014372A (es) | Compuestos derivados de 1,3,4-oxadiazol como inhibidores de histona desacetilasa 6, y la composicion farmaceutica que comprende los mismos. | |
WO2017134685A3 (en) | Novel hydrazino compounds as btk inhibitors | |
PH12021551232A1 (en) | Haloallylamine compounds and application thereof | |
MX2022005985A (es) | Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo. | |
WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
MX2019007213A (es) | Derivado de azaciclobutil triazol del grupo anular condensado, metodo de preparacion del mismo y uso del mismo en medicina. | |
PH12019502510A1 (en) | Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof | |
MX2023011203A (es) | Derivado de cumarina para terapia o profilaxis de un trastorno proliferativo celular. | |
PH12020500436A1 (en) | Aromatic derivative, preparation method for same, and medical applications thereof | |
WO2016122288A3 (ko) | 베르베논 유도체 및 재관류 치료제를 포함하는 뇌혈관 질환, 동맥경화증 또는 심혈관 질환 치료 또는 예방용 병용 제제 | |
EP4338751A3 (en) | Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor | |
EA201690903A1 (ru) | Лечение глаукомы с использованием лаквинимода | |
EA201592058A1 (ru) | Применение ландиолола гидрохлорида в длительном лечении тахиаритмии | |
NZ708511A (en) | Methods for controlling blood pressure and reducing dyspnea in heart failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |